What Is Thymosin Alpha-1? Peptide Profile
Thymosin alpha-1 is a 28-amino-acid acetylated peptide from thymosin fraction 5, studied for immune modulation and approved as a medicine in some countries.
Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.
Thymosin alpha-1 is a 28-residue peptide with an acetylated N-terminus. It differs from most compounds in this category in two ways: it has a clinical literature spanning decades, and it has regulatory approval in a number of countries. It also carries a name that causes persistent confusion.
For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.
Key points
- Length: 28 amino acids, N-terminally acetylated.
- Origin: isolated from thymosin fraction 5, a thymus-derived preparation.
- Not related in sequence or function to thymosin beta-4 or TB-500.
- Reported activity: immune modulation, with effects described on T cell populations and innate signalling.
- Approved as a medicine in some jurisdictions; research-grade material is not a medicine.
The naming problem, settled
This confusion is worth clearing up first, because it recurs constantly in catalogues and forums.
| Thymosin alpha-1 | Thymosin beta-4 / TB-500 | |
|---|---|---|
| Length | 28 residues | 43 residues (beta-4); TB-500 is a fragment |
| Sequence relationship | None — unrelated sequences | |
| Reported activity | Immune modulation | Actin binding, tissue repair contexts |
| Why the shared name | Both were isolated from the same thymus preparation, thymosin fraction 5 | |
The alpha and beta designations came from how the peptides behaved during separation of that fraction — a historical accident of purification chemistry, not a statement of molecular kinship. Treating them as variants of one thing is simply an error. See how the thymosin fragments compare and what TB-500 is.
The fraction 5 story
Thymosin fraction 5 was a partially purified thymus extract used in immunology research when the thymus’s role in T cell development was being worked out. It had measurable biological activity but was a mixture.
The subsequent work — separating that mixture and characterising individual peptides — is a good illustration of a general pattern in peptide research. Activity is found in a crude preparation, then components are isolated, and the activity may turn out to belong to one component, several, or to the combination. Thymosin alpha-1 is one of the components that retained activity on its own.
What the literature covers
| Source | Type | Scope |
|---|---|---|
| Ancell et al., 2001 (Am J Health Syst Pharm) | Pharmacy review | Written from a formulary standpoint — unusually concrete on properties and status |
| King et al., 2016 (Vitam Horm) | Review | Immune modulation mechanisms |
| Dominari et al., 2020 (World J Virol) | Comprehensive review | Broad survey of the literature to that point |
A 2025 review in the International Journal of Molecular Sciences addresses thymosin alpha-1 in the context of ageing, and further work examines its role in oncology immunoregulation. The field is active.
The 2001 pharmacy review is the one most worth reading first, and for a non-obvious reason: reviews written for pharmacists have to state what is actually known about a compound’s properties, formulation and evidence base, without the latitude a mechanistic review allows. For a peptide surrounded by loose claims, that discipline is useful.
The approved-medicine distinction
Thymosin alpha-1 has been approved and marketed in several countries. This has a specific consequence for anyone reading about it: much of the clinical literature concerns a pharmaceutical product manufactured under medicinal-product controls, which is not the same thing as research-grade peptide of the same sequence.
Differences that matter include manufacturing controls and documented impurity profiles, formulation and excipients, and verified N-terminal acetylation. Research material carries a certificate of analysis; a medicine carries a marketing authorisation. Conclusions from clinical studies of the latter do not transfer automatically to the former, and approval in one country says nothing about status elsewhere.
Handling in the lab
- Supplied lyophilized; store sealed at −20 °C, protected from light and moisture.
- Confirm N-terminal acetylation on the certificate. The acetyl group adds 42 Da, so the intact mass distinguishes the acetylated from the free-amine form.
- Reconstitute gently down the vial wall and swirl; aliquot rather than freeze–thawing repeatedly. See storing reconstituted peptides.
- At 28 residues the peptide is long enough that deletion impurities from synthesis are plausible — examine the HPLC trace, not only the mass.
- Concentration maths: peptide reconstitution calculator.
Our thymosin alpha-1 research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report.
Open questions
- Which receptor or receptors mediate the reported immune effects?
- How closely does research-grade peptide reproduce results obtained with the pharmaceutical product?
- What accounts for the differences in approval status across jurisdictions?
Related research
- Thymosin fragments compared
- What is LL-37?
- What is ARA-290?
Frequently asked questions
What is thymosin alpha-1?
Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminus, originally isolated from thymosin fraction 5, a preparation derived from thymus tissue. It is studied as an immunomodulatory peptide.
Is thymosin alpha-1 related to TB-500?
Only by shared naming history. Thymosin alpha-1 and thymosin beta-4 were both isolated from the same thymus preparation, but they are unrelated in sequence and function. TB-500 relates to thymosin beta-4. The shared word thymosin reflects the source tissue, not a molecular family.
What was thymosin fraction 5?
A partially purified preparation from thymus tissue, used in early immunology research. Several distinct peptides were later isolated from it, including thymosin alpha-1 and thymosin beta-4, and given alpha and beta designations based on their behaviour during separation.
Is thymosin alpha-1 an approved medicine?
It has been approved and marketed in a number of countries for certain indications, which is unusual among research peptides. Approval status differs by jurisdiction, and material supplied for research use is not a medicine.
Why does the N-terminal acetyl group matter?
N-terminal acetylation is present on the natural peptide and affects both stability and activity. A non-acetylated peptide of the same sequence is a different molecule, so the certificate of analysis should confirm acetylation.
References
- Ancell CD, et al. Thymosin alpha-1. Am J Health Syst Pharm. 2001. PMID: 11381492 https://pubmed.ncbi.nlm.nih.gov/11381492/
- King R, et al. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016. PMID: 27450734 https://pubmed.ncbi.nlm.nih.gov/27450734/
- Dominari A, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020. PMID: 33362999 https://pubmed.ncbi.nlm.nih.gov/33362999/
For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.